A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

NCT05804162 · Completed

Last updated 2026-05-28

This study is testing how a medication called cagrilintide affects heart rhythm in healthy adults who are obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 107 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2023-04 · est. completion 2023-09

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT05804162 ↗

Description as written by the study sponsor.

The study tests if treatment with cagrilintide delays the transmission of electrical signals in the heart compared to treatment with placebo. To confirm the sensitivity of the methodology, the drug moxifloxacin is also compared to a placebo in 2 treatment arms. Cagrilintide is being developed for the treatment of obesity and weight management. Moxifloxacin is an approved antibiotic for the treatment of bacterial illnesses. The study lasts for up to 17 weeks for each participant.

Treatments tested

Cagrilintide also known as Cagrilintide A, NNC0174-0833 A Drug

Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
Cagrilintide Placebo also known as Cagrilintide A, NNC0174-0833 A Drug

Participants will receive cagrilintide placebo subcutaneously once weekly.
Moxifloxacin also known as Moxifloxacinratiopharm Drug

Partcipants will receive a single dose of moxifloxacin orally.
Moxifloxacin Placebo Drug

Partcipants will receive a single dose of moxifloxacin orally.

Main thing measured	Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) At 12, 24, 48 and 72 Hours Post-Second Dose of Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose Level
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05804162 ↗